本文選題：恩替卡韋 + 慢性乙型肝炎　； 參考：《石河子大學(xué)》2017年碩士論文

【摘要】：背景:恩替卡韋對(duì)HBV抗病毒治療療效的研究是核苷類似物抗病毒治療的重要內(nèi)容,臨床上已經(jīng)注意到恩替卡韋對(duì)慢性乙型病毒性肝炎(CHB)不同臨床時(shí)期的抗病毒治療療效差異,而B(niǎo)、C基因型的CHB不同臨床時(shí)期是否影響恩替卡韋對(duì)CHB的抗病毒療效,目前報(bào)道較少,明確恩替卡韋對(duì)B、C基因型CHB患者之間的臨床療效差異,指導(dǎo)恩替卡韋對(duì)B、C基因型乙肝患者的臨床用藥,爭(zhēng)取最大限度的長(zhǎng)期抑制HBV復(fù)制,減輕肝細(xì)胞炎癥壞死,從而改善患者的生活質(zhì)量并延長(zhǎng)其生存時(shí)間。特別是在其他藥物抗病毒療效欠佳、耐藥率高且患者依從性差的情況下,通過(guò)恩替卡韋對(duì)B、C基因型CHB患者之間的臨床療效差異性觀察,對(duì)促進(jìn)臨床乙肝病毒治療提供理論支持具有重要意義。目的:分析恩替卡韋對(duì)B、C基因型CHB患者之間的抗病毒治療療效并比較差異性。方法:對(duì)我院符合標(biāo)準(zhǔn)的初始抗病毒治療的慢性乙型病毒性肝炎肝炎期、肝硬化代償期及肝硬化失代償期患者住院資料進(jìn)行回顧性分析。根據(jù)納入標(biāo)準(zhǔn)及排除標(biāo)準(zhǔn)納入,分別觀察CHB患者在經(jīng)恩替卡韋治療4、12、24及48周時(shí),HBVDNA載量、HBsAg定量、TBIL定量、ALB定量及ALT水平。治療結(jié)束后觀察HBeAg血清學(xué)轉(zhuǎn)換情況及肝硬化失代償期中腹水,消化道出血及肝性腦病的再發(fā)情況。結(jié)果:共納入初始抗病毒治療的B基因型CHB患者60例、C基因型CHB患者100例,(1)性別分布,男性119人,占病例總數(shù)的74.37%(119/160),女性41人,占病例總數(shù)的25.63%(41/160)。男女比例2.9:1,男性感染HBV的幾率明顯高于女性2倍以上。(2)年齡分布,30-50歲的患者比例最高,占病例總數(shù)的63.75%(102/160)。(3)CHB患者治療基線時(shí)水平:160例B、C基因型CHB患者治療前HBVDNA載量、HBsAg定量及ALT水平比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。但肝炎期、肝硬化代償期與肝硬化失代償期患者相比,血清總膽紅素(TBIL)、血清白蛋白水平(ALB)差異有統(tǒng)計(jì)學(xué)意義(P0.05)。(4)160例CHB患者治療后HBVDNA載量及ALT水平較基線時(shí)均有明顯下降,治療結(jié)束時(shí)HBVDNA陰轉(zhuǎn)率81.25%,ALT復(fù)常率78.75%,但B、C基因型兩組患者HBVDNA載量變化及ALT復(fù)常率差異無(wú)統(tǒng)計(jì)學(xué)意義。(5)肝炎期及肝硬化代償期與肝硬化失代償期患者相比,在治療4、12、24及48周時(shí),HBVDNA陰轉(zhuǎn)率及ALT陰轉(zhuǎn)率差異均具有統(tǒng)計(jì)學(xué)意義(P0.05),HBsAg陰轉(zhuǎn)率無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。(6)B基因型CHB患者肝硬化失代償期經(jīng)恩替卡韋治療48周后療效顯著,至治療結(jié)束時(shí),肝硬化失代償期并腹水患者、肝硬化失代償期并出血患者及肝硬化失代償期并肝性腦病患者均較基線時(shí)好轉(zhuǎn),差異具有統(tǒng)計(jì)學(xué)意義(P0.05),同樣,C基因型CHB患者肝硬化失代償期經(jīng)恩替卡韋治療48周后療效與基線時(shí)相比也得到相似結(jié)果,但相同時(shí)期的B、C兩基因型患者之間相比,無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。(7)相同時(shí)期的B、C基因型之間相比,HBVDNA陰轉(zhuǎn)率、ALT陰轉(zhuǎn)率ALB復(fù)常率、TBIL復(fù)常率及HBsAg陰轉(zhuǎn)率均無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:1.恩替卡韋抗病毒治療療效與B、C基因型無(wú)關(guān)。
[Abstract]:Background: entecavir's antiviral treatment for HBV is an important part of the antiviral therapy of nucleoside analogues. It has been noted that entecavir has different therapeutic effects on the antiviral treatment of chronic hepatitis B (CHB) in different clinical periods, and whether B, C genotype CHB affects the resistance of entecavir to CHB The efficacy of the virus is less reported. The clinical effect of entecavir on B and C genotype CHB patients is clearly defined. It guides the clinical use of entecavir for B and C genotype hepatitis B patients, strives for the maximum long-term inhibition of HBV replication and alleviating inflammatory necrosis of the liver cells, improving the quality of life and prolonging the survival time of the patients. It is of great significance to provide theoretical support for the promotion of clinical hepatitis B virus therapy through the observation of the clinical efficacy of entecavir on B and C genotype CHB in the case of poor antiviral effect, high drug resistance and poor compliance. Methods: a retrospective analysis was made to the data of patients with chronic hepatitis B, liver cirrhosis and decompensated cirrhosis in our hospital, which accords with the standard initial antiviral treatment. According to the inclusion criteria and exclusion criteria, the patients with CHB were treated with entecavir to treat 4,12,2 respectively. 4 and 48 weeks, HBVDNA load, HBsAg quantitative, TBIL quantitative, ALB quantitative and ALT level. After the treatment, the serological conversion of HBeAg and the recurrence of ascites, digestive tract hemorrhage and hepatic encephalopathy were observed. Results: 60 cases of B based CHB patients were included in the initial antiviral treatment, 100 cases of C genotype CHB patients, and (1) sex. The distribution, 119 men, accounted for 74.37% (119/160) of the total cases, 41 women, 25.63% (41/160) of the total cases. The ratio of men and women was 2.9:1, the rate of male infection of HBV was significantly higher than that of women. (2) age distribution, the proportion of 30-50 year old patients was the highest, accounting for 63.75% (102/160). (3) CHB patients at the baseline level: 160 B, C gene. There was no significant difference in the HBVDNA load, HBsAg quantitative and ALT levels before treatment for patients with CHB (P0.05). However, the serum total bilirubin (TBIL) and serum albumin level (ALB) were statistically significant (P0.05) compared with the patients with decompensated cirrhosis (P0.05). (4) the HBVDNA load and ALT level after treatment in 160 cases of CHB patients. The HBVDNA negative rate was 81.25% and the ALT recurrence rate was 78.75% at the end of the treatment, but there was no significant difference in the HBVDNA load and the ALT recurrence rate in the two groups of B and C genotypes. (5) the rate of HBVDNA negative and ALT negative in the 4,12,24 and 48 weeks after the treatment of liver cirrhosis and the decompensation period of liver cirrhosis. The difference in rate of rate was statistically significant (P0.05), and there was no statistical difference in the negative rate of HBsAg (P0.05). (6) the effect of the decompensation period of the B genotype CHB patients was significant after 48 weeks of entecavir treatment, and at the end of the treatment, the decompensated cirrhosis and ascites, the decompensated cirrhosis and the liver cirrhosis and hepatic encephalopathy at the end of the treatment. The patients were all better than the baseline (P0.05). Similarly, the curative effect of C genotype CHB patients after 48 weeks of entecavir treatment was similar to that of baseline, but there was no statistical difference between B and C two genotypes at the same time (P0.05). (7) the B, C genotypes at the same time. Compared with HBVDNA negative conversion rate, ALT negative rate ALB repetition rate, TBIL repetition rate and HBsAg negative rate, there was no statistical difference (P0.05). Conclusion: 1. the antiviral effect of entecavir is not related to B, C genotype.
【學(xué)位授予單位】：石河子大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張紹斌;楊超;;恩替卡韋治療失代償期慢性乙型病毒性肝炎肝硬化的臨床研究[J];實(shí)用臨床醫(yī)藥雜志;2016年05期

2 羅東鳳;丁南;;恩替卡韋治療代償期和失代償期乙肝肝硬化療效比較[J];海南醫(yī)學(xué);2015年23期

3 郭英君;黃雪梅;楊妍;郭英;閆蕾;;恩替卡韋聯(lián)合門冬氨酸鳥(niǎo)氨酸治療乙肝肝硬化肝性腦病效果觀察[J];中國(guó)社區(qū)醫(yī)師;2015年30期

4 Hasan Tahsin Gozdas;Erkan Arpaci;;Use of entecavir in hepatitis B virus reactivation of a patient with non-Hodgkin's lymphoma[J];World Journal of Gastroenterology;2015年35期

5 ;慢性乙型肝炎特殊患者抗病毒治療專家共識(shí):2015年更新[J];臨床肝膽病雜志;2015年08期

6 梁世寅;;恩替卡韋治療慢性乙型肝炎病毒感染患者臨床療效觀察[J];現(xiàn)代診斷與治療;2015年15期

7 馬艷紅;;乙型肝炎病毒基因分型特征及對(duì)抗病毒療效的影響[J];肝臟;2015年06期

8 夏淑林;何小峰;;恩替卡韋治療慢性乙型肝炎的療效觀察[J];臨床肝膽病雜志;2015年04期

9 蔣進(jìn)發(fā);陳國(guó)勇;趙明海;張宇;魏思東;;恩替卡韋抗病毒治療對(duì)肝癌HBV感染患者術(shù)后預(yù)后的影響[J];中國(guó)現(xiàn)代醫(yī)學(xué)雜志;2014年33期

10 柳雅;吳金明;陳梅琴;;恩替卡韋治療乙型肝炎肝硬化與慢性乙型肝炎96周的療效[J];臨床薈萃;2014年06期

相關(guān)博士學(xué)位論文 前1條

1 鄒勇;肝臟自然殺傷細(xì)胞在病毒誘導(dǎo)的肝衰竭中的作用[D];華中科技大學(xué);2009年

，

本文編號(hào)：1913042